Cyclooxygenase 2 Inhibitors
"Cyclooxygenase 2 Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subclass of cyclooxygenase inhibitors with specificity for CYCLOOXYGENASE-2.
Descriptor ID |
D052246
|
MeSH Number(s) |
D27.505.519.389.310.500 D27.505.696.663.850.014.040.500.500.500 D27.505.954.158.030.500.500 D27.505.954.329.030.500.500
|
Concept/Terms |
Cyclooxygenase 2 Inhibitors- Cyclooxygenase 2 Inhibitors
- Inhibitors, Cyclooxygenase 2
- Cyclooxygenase-2 Inhibitors
- Inhibitors, Cyclooxygenase-2
- Coxibs
- COX-2 Inhibitors
- COX 2 Inhibitors
- Inhibitors, COX-2
- COX2 Inhibitors
- Inhibitors, COX2
|
Below are MeSH descriptors whose meaning is more general than "Cyclooxygenase 2 Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Cyclooxygenase 2 Inhibitors".
This graph shows the total number of publications written about "Cyclooxygenase 2 Inhibitors" by people in this website by year, and whether "Cyclooxygenase 2 Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2001 | 0 | 1 | 1 |
2002 | 0 | 1 | 1 |
2003 | 0 | 1 | 1 |
2005 | 1 | 0 | 1 |
2006 | 0 | 1 | 1 |
2007 | 0 | 1 | 1 |
2010 | 1 | 0 | 1 |
2011 | 1 | 1 | 2 |
2012 | 0 | 2 | 2 |
2015 | 1 | 0 | 1 |
2017 | 0 | 1 | 1 |
2018 | 1 | 0 | 1 |
2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclooxygenase 2 Inhibitors" by people in Profiles.
-
Yarla NS, Madka V, Pathuri G, Rao CV. Molecular Targets in Precision Chemoprevention of Colorectal Cancer: An Update from Pre-Clinical to Clinical Trials. Int J Mol Sci. 2020 Dec 17; 21(24).
-
Mohammed A, Yarla NS, Madka V, Rao CV. Clinically Relevant Anti-Inflammatory Agents for Chemoprevention of Colorectal Cancer: New Perspectives. Int J Mol Sci. 2018 Aug 08; 19(8).
-
Rader JS, Sill MW, Beumer JH, Lankes HA, Benbrook DM, Garcia F, Trimble C, Tate Thigpen J, Lieberman R, Zuna RE, Leath CA, Spirtos NM, Byron J, Thaker PH, Lele S, Alberts D. A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 05; 145(2):291-297.
-
Rao CV, Janakiram NB, Madka V, Devarkonda V, Brewer M, Biddick L, Lightfoot S, Steele VE, Mohammed A. Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma. Oncotarget. 2015 Oct 20; 6(32):33290-305.
-
Wang SV, Schneeweiss S, Maclure M, Gagne JJ. "First-wave" bias when conducting active safety monitoring of newly marketed medications with outcome-indexed self-controlled designs. Am J Epidemiol. 2014 Sep 15; 180(6):636-44.
-
Pham TT, Miller MJ, Harrison DL, Lloyd AE, Crosby KM, Johnson JL. Cardiovascular disease and non-steroidal anti-inflammatory drug prescribing in the midst of evolving guidelines. J Eval Clin Pract. 2013 Dec; 19(6):1026-34.
-
Rao CV, Mohammed A, Janakiram NB, Li Q, Ritchie RL, Lightfoot S, Vibhudutta A, Steele VE. Inhibition of pancreatic intraepithelial neoplasia progression to carcinoma by nitric oxide-releasing aspirin in p48(Cre/+)-LSL-Kras(G12D/+) mice. Neoplasia. 2012 Sep; 14(9):778-87.
-
Bhattacharjee H, Nadipuram A, Kosanke S, Kiani MF, Moore BM. Low-volume binary drug therapy for the treatment of hypovolemia. Shock. 2011 Jun; 35(6):590-6.
-
Joyner PM, Waters AL, Williams RB, Powell DR, Janakiram NB, Rao CV, Cichewicz RH. Briarane diterpenes diminish COX-2 expression in human colon adenocarcinoma cells. J Nat Prod. 2011 Apr 25; 74(4):857-61.
-
Vinukonda G, Csiszar A, Hu F, Dummula K, Pandey NK, Zia MT, Ferreri NR, Ungvari Z, LaGamma EF, Ballabh P. Neuroprotection in a rabbit model of intraventricular haemorrhage by cyclooxygenase-2, prostanoid receptor-1 or tumour necrosis factor-alpha inhibition. Brain. 2010 Aug; 133(Pt 8):2264-80.